Prediabetes is a widespread yet largely silent metabolic condition, affecting over one-third of adults in the United States and more than one-fifth of adults across Europe. It occurs when blood sugar levels rise above the normal range but remain below the threshold for a full type 2 diabetes diagnosis. Given its scale, the prediabetes market represents a substantial and largely untapped opportunity, since no drug has yet received US FDA approval specifically for this indication.
Understanding Prediabetes Causes and Symptoms
Prediabetes causes are closely tied to lifestyle and genetic factors, including obesity, sedentary behavior, and a family history of type 2 diabetes. Because the condition often develops without obvious warning signs, many people remain unaware they have it. When present, prediabetes symptoms may include increased hunger, fatigue, blurred vision, and excessive thirst. This lack of overt signs makes routine screening especially important for early identification.
Prediabetes Screening and Diagnosis
Prediabetes screening typically begins at age 35 for most adults, though earlier testing is recommended for those who are overweight or carry additional risk factors. Prediabetes diagnosis relies on three main tests: the haemoglobin A1c test (values between 5.7% and 6.4%), the oral glucose tolerance test, and the fasting plasma glucose test, where readings of 100–125 mg/dL indicate the condition. Diagnosis is usually confirmed through repeat testing on a separate day.
Prediabetes Prevalence and Epidemiology
Prediabetes prevalence is striking: roughly 98 million adults aged 18 and older are affected in the United States alone, and prevalence is generally higher among men and individuals with obesity. Regional variation is notable too — figures range from 11% in England to as high as 30% in France under American Diabetes Association criteria. Prediabetes epidemiology data also show that the condition progresses to type 2 diabetes in about 30% of cases within three to five years, and up to 70% of individuals will eventually develop overt diabetes in their lifetime, underscoring the urgency around prediabetes complications prevention.
Prediabetes Prevention and Management
Prediabetes prevention centers on lifestyle change — a balanced diet low in added sugar and refined carbohydrates, regular physical activity, and modest weight reduction of 5–7%, which together can lower diabetes risk by more than half. Effective prediabetes management typically takes a multimodal approach, combining dietary adjustment, exercise, psychological support, and, where appropriate, medication, increasingly supported by wearables and digital health platforms.
Prediabetes Treatment Options and Medication
Currently, there are no drugs approved exclusively for prediabetes treatment; instead, prediabetes treatment options rely on medicines originally developed for type 2 diabetes, prescribed off-label. Common prediabetes drugs include metformin, which improves insulin sensitivity and lowers glucose production, along with DPP-IV inhibitors such as vildagliptin and alpha-glucosidase inhibitors that reduce post-meal glucose spikes. GLP-1 receptor agonists represent a promising class of prediabetes medication, shown to meaningfully reduce fasting glucose and HbA1c levels.
Prediabetes Pipeline and Emerging Therapies
The prediabetes pipeline remains relatively thin compared with other chronic disease markets, but a handful of prediabetes emerging therapies are progressing through prediabetes clinical trials. Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, is in Phase III development for obesity and prediabetes; its STEP 10 trial demonstrated superior weight reduction and a return to normal blood sugar levels compared with placebo. Aphaia Pharma’s APH-012, evaluated in a Phase II trial, met its primary endpoint by significantly improving glucose tolerance within six weeks, a milestone often referenced as APHD-012 in company communications, with trials ongoing in the US, Germany, and Slovakia. This prediabetes drug pipeline activity reflects a slowly maturing prediabetes therapeutic landscape.
Prediabetes Market Size, Forecast, and Trends
According to DelveInsight’s market analysis, the US prediabetes market holds the largest share among the seven major markets (7MM), which include the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The prediabetes market size and prediabetes market forecast through 2034 point to continued expansion, driven by rising obesity, an ageing population, and growing diagnosis rates. Broader prediabetes market trends highlight the role of digital health tools and wearables in reshaping patient engagement. The prediabetes 7mm market outlook, detailed in DelveInsight’s comprehensive prediabetes market report and prediabetes market analysis, offers pharmaceutical companies critical insight into unmet needs, competitive positioning, and reimbursement dynamics.
Prediabetes Pharmaceutical Companies Driving Innovation
Several prediabetes pharmaceutical companies, notably Novo Nordisk and Aphaia Pharma, are shaping the current prediabetes treatment landscape. As diagnosis rates climb and lifestyle-driven risk factors persist, the market is poised for meaningful transformation — provided emerging therapies can navigate regulatory pathways toward the first dedicated approval in this space.
Latest Reports Offered by Delveinsight
neuroprosthetics market | optical coherence tomography devices market | osteosarcoma market | pulmonary arterial hypertension market | pulse oximeter market | schizophrenia market | spinal stenosis market | structural heart devices market | uveitis market | vascular imaging devices market | vulvar cancer market | walking impairment in multiple sclerosis market | 3d cardiac mapping system market | achondroplasia market | acromegaly market | acute ischemic stroke ais market | acute myeloid leukemia market | acute on chronic liver failure aclf market | acute pulmonary embolism market | adhd market | adrenomyeloneuropathy market | aicardi-goutières syndrome market | aids dementia market | alagille syndrome market | alpha-mannosidosis market | alport syndrome market | alstrom syndrome market | alzheimer disease market | alzheimer’s disease market | amyotrophic lateral sclerosis market | androgenetic alopecia market | ankylosing spondylitis market | arteriovenous malformations market | artificial cornea and corneal implan market | atopic dermatitis market | atrial fibrillation market | audiology devices market | autoimmune hepatitis market
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk